News‎ > ‎

AurimMed’s Announcements


  • October, 2016 Patent offices of Singapore and South Korea issued patent for AurimMed CNS-active compounds
  • December,  2015 The United States Patent  and Trademark Office issued patent for AurimMed CNS-active compounds
  • November, 2015 The Mexican Patent Office issued Mexico patent for AurimMed CNS-active compounds
  • October, 2015  AurimMed presented its Parkinson and SMA results at Society for Neuroscience (Chicago, IL)
  • August, 2015   The in vivo test results suggest that oral treatment of AMP-X-0079 for two weeks significantly reduced the MPTP-induced abnormal involuntary hindlimb clasping and improved the grooming behavior and motor coordination in MPTP-lesioned mice. The immunohistochemical analyses suggested that oral AMP-X-0079 treatment for two weeks can effectively induce recovery effect from MPTP-induced lesion in the midbrain and the striatum
  • July, 2015   Monograph on AurimMed’s lead, AMP-X-0079, antiepileptic candidate published in NIHRed Book
  • June, 2015  AurimMed presented its SMA results at Cure SMA Research Annual meeting (Kansas City, MO) 
  • May, 2015  Patent offices for Australia and Japan issued patent for AurimMed CNS-active compounds
  • February 2015  Patent Office of the People’s Republic of China issued patent for AurimMed CNS-active compounds
  • September, 2014  AurimMed presented its work at EILAT Conference XII (Madrid, Spain)
  • June, 2014     AurimMed presented its work at Epilepsy Pipeline Conference  (San Francisco, CA)
  •  March, 2014  Data obtained from Delaware State University collaboration showed AurimMed compounds have potent neuroprotective effects against oxidative stress (mediated by both H2Oand MPP+) in Parkinson’s Disease in vitro models.
  • March, 2014   AurimMed’s lead candidate, AMP-X-0079, is one of the very few compounds capable of terminating ongoing status epilepticus seizures due to a nerve agent and It controls seizure rapidly within, typically less than 15 min.
  •  March, 2014   Research collaboration established with the Delaware State University, to investigate AurimMed compounds activity in tests for effectiveness in oxidative stress assays thought to model Parkinson’s disease (PD).
  • November, 2013   Renewal of Agreement (MTA) with Department of Defense (DOD)
  • October, 2013   Research collaboration with the Nemours Alfred I. DuPont Hospital for Children, demonstrates that AurimMed lead candidates have remarkable activity in tests for expression of SMN2, which is a current therapeutic target for treatment of Spinal Muscular Atrophy (SMA).
  • September, 2013   Research collaboration established with the Nemours Alfred I. DuPont Hospital for Children, to test AurimMed lead candidates for activity in in vitro assays related to therapeutic targets for Spinal Muscular Atrophy (SMA) (SMN2 expression)
  • September, 2013   NIH data establish that AMP-X-0079 prevents cognitive deficits, preserves spatial learning and memory, and provides neuroprotection in vivo.
  • December, 2012   AurimMed’s lead compound found effective by NIH-ASP in model of drug-resistant epilepsy.
  • December, 2010  Monograph on AurimMed’s lead antiepileptic candidate published in NIHRed Book.
  • November, 2009  Testing by U.S. Army Medical Research Institute of Chemical Defense (DOD) demonstrates AurimMed’s lead compound has significant activity in suppressing and eliminating severe seizures induced by Soman (a highly toxic nerve agent).
  • October, 2009  Material Transfer Agreement (MTA) established with Department of Defense (DOD) for testing AurimMed’s compounds as chemical countermeasures in U.S. CounterACT Program.
  • July, 2009  NIH testing demonstrates AurimMed compounds have significant analgesic activity against inflammatory and neuropathic pain.
  • April, 2009  AurimMed presents its work on novel anticonvulsants at 10th Antiepileptic Drug Trials Conference, Coral Gables, FL.
  • January, 2009   AurimMed compounds found to be non-toxic in Cell Proliferation assays by Stem Cell Innovations®, Inc.
  • September, 2008 AurimMed antiepileptic compounds tested by Stem Cell Innovations®, Inc. in Human Liver Cell assays showing that AurimMed’s compounds are not cell or liver toxic at high concentrations.
  • July, 2008  NIH data demonstrate AurimMed’s lead candidates active against status epilepticus.
  • March, 2007  AurimMed Pharma established.
 
Comments